For most patients receiving immune-based treatments for inflammatory skin disorders, the therapy can be continued without affecting protective vaccine-induced immunity.

For some drugs, temporary treatment interruption or administration of the vaccine at the optimal period according to the pharmacokinetics of the drug and the individual level of disease control can be considered.